4.6 Article

Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers

Journal

ACTA NEUROPATHOLOGICA
Volume 130, Issue 4, Pages 559-573

Publisher

SPRINGER
DOI: 10.1007/s00401-015-1474-4

Keywords

Amyotrophic lateral sclerosis; C9ORF72 repeat expansion; c9RAN proteins; Cognition; Dipeptide repeat proteins; Frontotemporal dementia; Frontotemporal lobar degeneration; Neuropathological diagnosis; Repeat-associated non-ATG translation

Funding

  1. National Institutes of Health/National Institute of Neurological Disorders and Stroke [R21NS089979, R21NS084528, R01NS088689, R01NS063964, R01NS077402, P01NS084974, R01NS080882, F32NS087842]
  2. Department of Defense [ALSRP AL130125]
  3. Mayo Clinic Foundation
  4. ALS Association
  5. Target ALS
  6. Robert Packard Center for ALS Research at Johns Hopkins
  7. ALS Therapy Alliance
  8. Ludwig Institute for Cancer Research
  9. European Union's Seventh Framework Programme [617198]
  10. Milton Safenowitz Post Doctoral Fellowship for ALS research from ALS Association
  11. Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Clinical Research Fellowship [U54NS092091]

Ask authors/readers for more resources

Clinical and neuropathological characteristics associated with G(4)C(2) repeat expansions in chromosome 9 open reading frame 72 (C9ORF72), the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, are highly variable. To gain insight on the molecular basis for the heterogeneity among C9ORF72 mutation carriers, we evaluated associations between features of disease and levels of two abundantly expressed c9RAN proteins produced by repeat-associated non-ATG (RAN) translation of the expanded repeat. For these studies, we took a departure from traditional immunohistochemical approaches and instead employed immunoassays to quantitatively measure poly(GP) and poly(GA) levels in cerebellum, frontal cortex, motor cortex, and/or hippocampus from 55 C9ORF72 mutation carriers [12 patients with ALS, 24 with frontotemporal lobar degeneration (FTLD) and 19 with FTLD with motor neuron disease (FTLD-MND)]. We additionally investigated associations between levels of poly(GP) or poly(GA) and cognitive impairment in 15 C9ORF72 ALS patients for whom neuropsychological data were available. Among the neuroanatomical regions investigated, poly(GP) levels were highest in the cerebellum. In this same region, associations between poly(GP) and both neuropathological and clinical features were detected. Specifically, cerebellar poly(GP) levels were significantly lower in patients with ALS compared to patients with FTLD or FTLD-MND. Furthermore, cerebellar poly(GP) associated with cognitive score in our cohort of 15 patients. In the cerebellum, poly(GA) levels similarly trended lower in the ALS subgroup compared to FTLD or FTLD-MND subgroups, but no association between cerebellar poly(GA) and cognitive score was detected. Both cerebellar poly(GP) and poly(GA) associated with C9ORF72 variant 3 mRNA expression, but not variant 1 expression, repeat size, disease onset, or survival after onset. Overall, these data indicate that cerebellar abnormalities, as evidenced by poly(GP) accumulation, associate with neuropathological and clinical phenotypes, in particular cognitive impairment, of C9ORF72 mutation carriers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available